MY118526A - Method for improving the pharmacokinetics of tipranavir - Google Patents
Method for improving the pharmacokinetics of tipranavirInfo
- Publication number
- MY118526A MY118526A MYPI99004794A MYPI9904794A MY118526A MY 118526 A MY118526 A MY 118526A MY PI99004794 A MYPI99004794 A MY PI99004794A MY PI9904794 A MYPI9904794 A MY PI9904794A MY 118526 A MY118526 A MY 118526A
- Authority
- MY
- Malaysia
- Prior art keywords
- tipranavir
- pharmacokinetics
- improving
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
- SUJUHGSWHZTSEU-UHFFFAOYSA-N Tipranavir Natural products C1C(O)=C(C(CC)C=2C=C(NS(=O)(=O)C=3N=CC(=CC=3)C(F)(F)F)C=CC=2)C(=O)OC1(CCC)CCC1=CC=CC=C1 SUJUHGSWHZTSEU-UHFFFAOYSA-N 0.000 title abstract 3
- 229960000838 tipranavir Drugs 0.000 title abstract 3
- SUJUHGSWHZTSEU-FYBSXPHGSA-N tipranavir Chemical compound C([C@@]1(CCC)OC(=O)C([C@H](CC)C=2C=C(NS(=O)(=O)C=3N=CC(=CC=3)C(F)(F)F)C=CC=2)=C(O)C1)CC1=CC=CC=C1 SUJUHGSWHZTSEU-FYBSXPHGSA-N 0.000 title abstract 3
- 150000003839 salts Chemical class 0.000 abstract 2
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 abstract 1
- 229960000311 ritonavir Drugs 0.000 abstract 1
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10696398P | 1998-11-04 | 1998-11-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY118526A true MY118526A (en) | 2004-11-30 |
Family
ID=22314155
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI99004794A MY118526A (en) | 1998-11-04 | 1999-11-04 | Method for improving the pharmacokinetics of tipranavir |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US6147095A (enExample) |
| EP (1) | EP1126847A1 (enExample) |
| JP (1) | JP2002528502A (enExample) |
| CN (1) | CN1154491C (enExample) |
| AU (1) | AU762349B2 (enExample) |
| BR (1) | BR9914940A (enExample) |
| CA (1) | CA2346131C (enExample) |
| CO (1) | CO5160321A1 (enExample) |
| HK (1) | HK1040625B (enExample) |
| MY (1) | MY118526A (enExample) |
| PE (1) | PE20001296A1 (enExample) |
| TW (1) | TW580387B (enExample) |
| WO (1) | WO2000025784A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9815567D0 (en) * | 1998-07-18 | 1998-09-16 | Glaxo Group Ltd | Antiviral compound |
| ES2298286T3 (es) * | 2000-10-31 | 2008-05-16 | Boehringer Ingelheim Pharmaceuticals Inc. | Formulaciones de dosis orales auto-emulsionantes de inhibidores de proteasa de piranona. |
| DE10108470A1 (de) * | 2001-02-22 | 2002-09-05 | Boehringer Ingelheim Pharma | Verfahren zur Herstellung optisch aktiver Dihydropyrone |
| US6500963B2 (en) | 2001-02-22 | 2002-12-31 | Boehringer Ingelheim Pharma Kg | Process for preparing optically active dihydropyrones |
| US20040197321A1 (en) * | 2002-03-19 | 2004-10-07 | Tibor Sipos | Composition and method to prevent or reduce diarrhea and steatorrhea in HIV patients |
| US20030180279A1 (en) * | 2002-03-19 | 2003-09-25 | Tibor Sipos | Composition and method to prevent or reduce diarrhea and steatorrhea in HIV patients |
| KR20050085681A (ko) * | 2002-12-16 | 2005-08-29 | 베링거 인겔하임 인터내셔날 게엠베하 | 프로테아제 억제제와 같은 사이토크롬 ｐ450의 억제제와함께 비-뉴클레오시드 역전사효소 억제제(ｎｎｒｔｉ)를함유하는 배합물의 용도 |
| AU2003295940A1 (en) * | 2002-12-16 | 2004-07-29 | Boehringer Ingelheim Pharmaceuticals, Inc. | Treatment of hiv infection through combined administration of tipranavir and capravirine |
| EP1610781A1 (en) * | 2003-03-27 | 2006-01-04 | Boehringer Ingelheim International GmbH | Antiviral combination of tipranavir and a further antiretroviral compound |
| AR045841A1 (es) * | 2004-09-28 | 2005-11-16 | Richmond Sa Com Ind Y Financie | Una composicion farmaceutica solida que comprende al tiazolil metil ester del acido [5s-(5r*, 8r*, 10r*,11r*)] -10- hidroxi-2- metil-5-(1-metiletil)-1-[2-(1-metiletil)-4-tiazolil]-3,6-dioxo-8,11-bis(fenilmetil)-2,4,7,12- tetraazatridecan-13-oico y un procedimiento para prepararla. |
| EP1812069A2 (en) * | 2004-11-08 | 2007-08-01 | Boehringer Ingelheim International GmbH | Method for treating hiv infection through co-administration of tipranavir and etravirine |
| US20060135562A1 (en) * | 2004-11-16 | 2006-06-22 | Boehringer Ingelheim International Gmbh | Method for treating HIV infection through co-administration of tipranavir and darunavir |
| EP1814549A2 (en) * | 2004-11-19 | 2007-08-08 | Boehringer Ingelheim International GmbH | Method for treating hiv infection through co-administration of tipranavir and uk-427, 857 |
| US20060128733A1 (en) * | 2004-11-19 | 2006-06-15 | Boehringer Ingelheim International Gmbh | Method for treating HIV infection through co-administration of tipranavir and reverset |
| WO2006060175A1 (en) * | 2004-12-01 | 2006-06-08 | Boehringer Ingelheim International Gmbh | Method for treating hiv infection through co-administration of tipranavir and sch-417690 |
| WO2006060177A1 (en) * | 2004-12-01 | 2006-06-08 | Boehringer Ingelheim International Gmbh | Method for treating hiv infection through co-administration of tipranavir and gw873140 |
| JP2008521896A (ja) * | 2004-12-01 | 2008-06-26 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | チプラナビル及びｇｗ６９５６３４を共に投与することを含むｈｉｖ感染症の治療方法 |
| WO2008112289A2 (en) | 2007-03-12 | 2008-09-18 | Nektar Therapeutics | Oligomer-protease inhibitor conjugates |
| WO2009114151A1 (en) * | 2008-03-12 | 2009-09-17 | Nektar Therapeutics | Oligomer-amino acid and olgomer-atazanavir conjugates |
| US20100021505A1 (en) * | 2008-07-28 | 2010-01-28 | Tibor Sipos | Composition and method to prevent or reduce diarrhea and steatorrhea in HIV patients |
| EP2440249A2 (en) | 2009-06-12 | 2012-04-18 | Nektar Therapeutics | Covalent conjugates comprising a protease inhibitor, a water-soluble, non-peptidic oligomer and a lipophilic moiety |
| MX2012011415A (es) * | 2010-04-02 | 2013-02-26 | Phivco 1 Llc | Terapia de combinacion que comprende un antagonista de ccr5, un inhibidor de proteasa de vih-1, y un potenciador farmacocinetico. |
| AU2012262322B2 (en) * | 2011-05-30 | 2016-11-03 | Autotelic Llc | Methods and compositions for therapeutic drug monitoring and dosing by point-of-care pharmacokinetic profiling |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5608085A (en) * | 1995-02-27 | 1997-03-04 | The University Of Tennessee Research Corporation | Synthesis of optically active calanolides A and B and enantiomers and related compounds |
| US6037157A (en) * | 1995-06-29 | 2000-03-14 | Abbott Laboratories | Method for improving pharmacokinetics |
| US5932570A (en) * | 1996-11-08 | 1999-08-03 | Dupont Pharmaceuticals Company | 1-(3-aminoindazol-5-yl)-3-phenylmethyl-cyclic ureas useful as HIV protease inhibitors |
| ZA9710071B (en) * | 1996-11-21 | 1998-05-25 | Abbott Lab | Pharmaceutical composition. |
-
1999
- 1999-10-29 HK HK02102194.8A patent/HK1040625B/zh not_active IP Right Cessation
- 1999-10-29 US US09/430,742 patent/US6147095A/en not_active Expired - Lifetime
- 1999-10-29 JP JP2000579225A patent/JP2002528502A/ja active Pending
- 1999-10-29 WO PCT/US1999/021469 patent/WO2000025784A1/en not_active Ceased
- 1999-10-29 EP EP99971319A patent/EP1126847A1/en active Pending
- 1999-10-29 AU AU14404/00A patent/AU762349B2/en not_active Expired
- 1999-10-29 CN CNB998123587A patent/CN1154491C/zh not_active Expired - Lifetime
- 1999-10-29 CA CA2346131A patent/CA2346131C/en not_active Expired - Lifetime
- 1999-10-29 BR BR9914940-0A patent/BR9914940A/pt not_active Application Discontinuation
- 1999-11-03 PE PE1999001100A patent/PE20001296A1/es not_active Application Discontinuation
- 1999-11-04 MY MYPI99004794A patent/MY118526A/en unknown
- 1999-11-04 CO CO99069669A patent/CO5160321A1/es unknown
- 1999-11-04 TW TW088119229A patent/TW580387B/zh not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2002528502A (ja) | 2002-09-03 |
| CO5160321A1 (es) | 2002-05-30 |
| EP1126847A1 (en) | 2001-08-29 |
| CN1154491C (zh) | 2004-06-23 |
| CN1324237A (zh) | 2001-11-28 |
| BR9914940A (pt) | 2001-07-10 |
| PE20001296A1 (es) | 2000-11-23 |
| CA2346131A1 (en) | 2000-05-11 |
| WO2000025784A1 (en) | 2000-05-11 |
| CA2346131C (en) | 2013-01-15 |
| AU762349B2 (en) | 2003-06-26 |
| TW580387B (en) | 2004-03-21 |
| AU1440400A (en) | 2000-05-22 |
| HK1040625B (zh) | 2005-04-01 |
| US6147095A (en) | 2000-11-14 |
| HK1040625A1 (en) | 2002-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2002042462A3 (en) | Therapeutic agents and methods of use thereof for treating an amyloidogenic disease | |
| UA56989C2 (uk) | ФІЗІОЛОГІЧНО АКТИВНИЙ ПЕГ-КОН'ЮГАТ <font face="Symbol">a</font>-ІНТЕРФЕРОНУ, СПОСІБ ЙОГО ОДЕРЖАННЯ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ НА ЙОГО ОСНОВІ ТА СПОСІБ ЛІКУВАННЯ АБО ПРОФІЛАКТИКИ ІМУНОМОДУЛЯТОРНИХ ЗАХВОРЮВАНЬ | |
| IL152659A (en) | Liquid pharmaceutical compositions comprising a pegylated human erythropoietin protein and a multiple charged inorganic anion, in a pharmaceutically acceptable buffer | |
| ZA977783B (en) | Method of inhibiting fibrosis with a somatostatin agonist | |
| EP1426375A3 (en) | Analgesic spiroindole derivatives | |
| NZ334124A (en) | Use of the chelating agent clioquinol, with vitamin B12 for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease | |
| UA41879C2 (uk) | Засіб для лікування мотонейронових захворювань | |
| CA2426703A1 (en) | Therapeutic agents and methods of use thereof for the modulation of angiogenesis | |
| BR9914940A (pt) | Método para aperfeiçoar a farmacocinética de tipranavir | |
| WO2005058233A3 (en) | Methods for treatment of acute pancreatitis | |
| UA41355C2 (uk) | Засіб для лікування нейро-сніду | |
| GB2368525A (en) | Hyaluronan as a cytotoxic agent, drug pre-sensitizer and chemo-sensitizer in the treatment of disease | |
| ZA200109322B (en) | A new use for deferiprone. | |
| GB0020504D0 (en) | Therapeutic method | |
| PL338673A1 (en) | Application of fanquinone in treating alzheimer disease | |
| WO2001045715A3 (en) | Combinations of an adenosine a1 agonist with an opioid and their use in the treatment of pain | |
| MX9707642A (es) | Uso de 2-oxoindol-1-carboxamidas 3-sustituidas y sus sales de base farmaceuticamente aceptables para preparar composiciones para el tratamiento y prevencion de la enfermedad de alzheimer en mamiferos, incluyendo a humanos. | |
| EP0744176A3 (en) | Methods for inhibiting bone loss | |
| AU1656997A (en) | Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of cancer | |
| YU45103A (sh) | Upotreba sarp/1 za lečenje i prevenciju skleroderme | |
| WO1999065475A3 (en) | Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction | |
| BG106151A (en) | Pharmaceutical complex | |
| EP0743068A3 (en) | Composition for inhibiting bone loss containing vanadyl sulfate | |
| IL126158A0 (en) | Method for treating substance abuse | |
| EP1712231A3 (en) | Method for improving the pharmacokinetics of tipranavir |